08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Jespect ixiaro regulatory update

The Taiwanese Food and Drug Administration (TFDA) approved Jeval from Adimmune to vaccinate against Japanese encephalitis (JE) infection. Adimmune has Taiwanese rights to develop and commercialize the product from Valneva under a 2014 deal (see...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Adimmune, Valneva deal

Valneva granted vaccine manufacturer Adimmune rights to develop and commercialize Valneva's Japanese Encephalitis (JE) vaccine in Taiwan. Adimmune will be responsible for obtaining regulatory approval in the country and will market the vaccine under a...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

ADImmune Corp., Crucell deal

ADImmune received an exclusive license to use CRXL's virosome technology to produce a virosomal adjuvanted influenza vaccine in Taiwan, Japan and Macau. ADImmune also will produce influenza antigen, which CRXL may purchase for its marketed...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

ADImmune Corp., Crucell deal

CRXL granted ADImmune a non-exclusive license use the PER.C6 cell line to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China. CRXL will receive a license issuance fee and annual maintenance...